skip to Main Content

GU Specialists

Ronald C. Chen, MD, MPH

Joe and Jean Brandmeyer Endowed Chair, Department of Radiation Oncology
Professor, Department of Radiation Oncology
Clinical Service Chief, Department of Radiation Oncology
Associate Director of Health Equity, University of Kansas Cancer Center Radiation Oncology

Dr. Chen is the Brandmeyer Professor and Chair of Radiation Oncology at the University of Kansas Cancer Center. An internationally-renowned radiation oncologist, Dr. Chen specializes in the treatment of GU cancers, and has helped write many of the national standards and guidelines on the treatment of prostate cancer, and lectures across the US and internationally on the treatment of prostate and bladder cancers. He is a leader in the American Society for Radiation Oncology (ASTRO), American Society of Clinical Oncology (ASCO), and several other national organizations.

In addition, Dr. Chen is a leading researcher with a research focus on finding the best treatment for prostate cancer, quality of life, and issues related to cancer survivorship. Dr. Chen has received many research grants, and has published more than 200 articles in peer-reviewed journals, including top journals such as JAMA, JAMA Oncology and the Journal of Clinical Oncology. Dr. Chen has written many textbook chapters on prostate and bladder cancers, and has published his own book on “Hypofractionated and Stereotactic Radiation Therapy.” Dr. Chen also leads or helps lead several ongoing national and international clinical trials in prostate, bladder and testicular cancers. Dr. Chen serves as an editor for the Red Journal and Practical Radiation Oncology.

Jeff Michalski, MD, MBA, FASTRO

Professor and Vice Chair of Radiation Oncology
Washington University School of Medicine

Dr. Michalski is the Carlos Perez Distinguished Professor, Vice-Chairman of the Department of Radiation Oncology, Director of the Clinical Sciences Division, and Chief of the Genitourinary Service. Dr. Michalski is Chairman of the Radiation Oncology Committee of the NRG Oncology Group, and is a member of the Bladder Cancer Panel of the National Comprehensive Cancer Network. He is Co-Chair of the NCI Genitourinary Cancers Steering Committee. He is a member of the Siteman Cancer Center at Washington University and Barnes-Jewish Hospital, and is the Medical Director of the center’s Clinical Trials Core. Dr. Michalski is a member of the ASTRO Board of Directors, currently serving as the Secretary/Treasurer. His research interests include radiation dose escalation in the management of prostate cancer; conformal therapy to reduce toxicity in late neuro-cognitive effects in children with medulloblastoma; and assessment of quality of life in survivors of adult and childhood malignancies.

Back To Top